221 Main Street, Suite 1350
4 articles with Atomwise
Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program
The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines.
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform
Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities
Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery.